• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    31753925.pdf
    Size:
    2.306Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Yakoub-Agha, I
    Chabannon, C
    Bader, P
    Basak, GW
    Bonig, H
    Ciceri, F
    Corbacioglu, S
    Duarte, RF
    Einsele, H
    Hudecek, M
    Kersten, MJ
    Kohl, U
    Kuball, J
    Mielke, S
    Mohty, M
    Murray, John
    Nagler, A
    Robinson, S
    Saccardi, R
    Sanchez-Guijo, F
    Snowden, JA
    Srour, M
    Styczynski, J
    Urbano-Ispizua, A
    Hayden, PJ
    Kroger, N
    Show allShow less
    Affiliation
    CHU de Lille, UniversitŽ de Lille, Lille, France
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    Chimeric antigen receptor T-cells are a novel class of anti-cancer therapy in which autologous or allogeneic T-cells are engineered to express a chimeric antigen receptor targeting a membrane antigen. In Europe, Tisagenlecleucel (KymriahTM) is approved for the treatment of refractory/relapsed Acute Lymphoblastic Leukaemia in children and young adults as well as relapsed/refractory Diffuse Large B-cell Lymphoma; Axicabtagene ciloleucel (YescartaTM) is approved for the treatment of relapsed/refractory high-grade B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. Both agents are genetically engineered autologous T-cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of chimeric antigen receptor T-cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological patient support, long-term follow-up, post-authorisation safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.
    Citation
    Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2019.
    Journal
    Haematologica
    URI
    http://hdl.handle.net/10541/622638
    DOI
    10.3324/haematol.2019.229781
    PubMed ID
    31753925
    Additional Links
    https://dx.doi.org/10.3324/haematol.2019.229781
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.3324/haematol.2019.229781
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    • Authors: Alsuliman T, Drieu La Rochelle L, Campidelli A, Duléry R, Fayard A, Mamez AC, Mear JB, Schneider PO, Trevet A, Vicente C, Yakoub-Agha I
    • Issue date: 2021 Dec
    • Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
    • Authors: Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I
    • Issue date: 2022 Mar
    • [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    • Authors: Carnoy S, Beaumont JL, Kanouni T, Parquet N, Beauvais D, Hequet O, Kanold J, Ballot C, Mialou V, Reppel L, Damaj G, Yakoub-Agha I, Chabannon C
    • Issue date: 2021 Mar
    • Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
    • Authors: Jacobson CA, Farooq U, Ghobadi A
    • Issue date: 2020 Jan
    • Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
    • Authors: Dushenkov A, Jungsuwadee P
    • Issue date: 2019 Jul
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.